Tomorrow, Silvio Danese, MD, PhD will present new preclinical findings during an oral presentation at #ECCO2026 highlighting emerging data exploring evidence of obefazimod’s anti-fibrotic activity in preclinical models of #IBD. View the abstract here: bit.ly/4s2ILPc

Today we shared updates on obefazimod at #ECCO2026: 🔬Preclinical data showing evidence of anti-fibrotic activity ✅Additional safety profile insights ⏱️Onset of symptomatic relief 📊Biomarker data from ABTECT-1 & ABTECT-2 Ph 3 induction trials Read more: bit.ly/3ZJKHjr